Abstracts tagged "proteomics and rheumatoid arthritis"

Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].